BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
Priority Review
KIMMTRAK (tebentafusp) by Immunocore is glycoprotein 100 peptide-human leukocyte antigen-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KIMMTRAK (tebentafusp) is a bispecific T-cell engager that redirects CD3+ T cells to recognize gp100-peptide-HLA complexes on tumor cells. It represents a novel class of immunotherapy designed to harness the patient's own immune system against melanoma and other gp100-expressing cancers. The mechanism bridges tumor-associated antigen recognition with T-cell activation, creating a dual-targeting approach.
Peak
Product is in peak commercial phase post-launch with moderate competitive pressure (30/100), indicating active promotion and market expansion efforts requiring robust commercial infrastructure.
Mechanism of Action
Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
Pharmacologic Class:
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
Started Nov 2026
34 enrolled
Uveal Melanoma, Metastatic
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Started Dec 2025
18 enrolled
Metastatic Uveal Melanoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Started Oct 2025
47 enrolled
HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
Neoadjuvant Tebentafusp for Uveal Melanoma
Started Sep 2025
19 enrolled
Locally Advanced Unresectable Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Started Aug 2025
44 enrolled
Uveal Melanoma
Worked on KIMMTRAK at Immunocore? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.